Coherence treatment of postmenopausal osteoporosis with growth hormone and calcitonin

Fourteen women with postmenopausal osteoporosis, all having at least one vertebral crush fracture, were randomly assigned to two treatment arms, each lasting 24 months. The coherence treatment group (7 patients) was treated in the following sequence: human growth hormone (hGH) 7 IU subcutaneously da...

Full description

Saved in:
Bibliographic Details
Published inCalcified tissue international Vol. 40; no. 5; p. 253
Main Authors Aloia, J F, Vaswani, A, Meunier, P J, Edouard, C M, Arlot, M E, Yeh, J K, Cohn, S H
Format Journal Article
LanguageEnglish
Published United States 01.05.1987
Subjects
Aged
Bone and Bones - analysis
Bone and Bones - pathology
Calcitonin - therapeutic use
Calcium - analysis
Drug Therapy, Combination
Female
Growth Hormone - therapeutic use
Humans
Menopause
Middle Aged
Minerals - analysis
Osteoporosis - drug therapy
Osteoporosis - metabolism
Osteoporosis - pathology
Online AccessGet more information

Cover

More Information
Summary:Fourteen women with postmenopausal osteoporosis, all having at least one vertebral crush fracture, were randomly assigned to two treatment arms, each lasting 24 months. The coherence treatment group (7 patients) was treated in the following sequence: human growth hormone (hGH) 7 IU subcutaneously daily for 2 months, followed by 3 months of salmon calcitonin (CT), 100 MRC units every other day. After a 3 month rest period, this sequence was repeated twice. The contrast group (7 patients) was treated intermittently with salmon CT given in the same time periods and at the same dose as in the coherence treatment group. Bone mass was measured every 4 months by neutron activation analysis for total body calcium (TBCa) and by single photon absorptiometry for bone mineral content (BMC) of the distal radius. Although there were no significant differences between the two groups (two-way ANOVA), the rate of change in TBCa in the coherence treatment group was significantly different from zero (F = 3.8, P less than .05) and was +2.3%/year. The increase in bone mass appeared to be sustained throughout the 2 year study, in contrast with previous studies where a plateau effect was observed with calcitonin given alone or continuously with growth hormone. No significant change was found in bone histomorphometric values measured before and after treatment in 4 patients from each group.
ISSN:0171-967X
DOI:10.1007/BF02555257